Renal amyloidosis in common variable immunodeficiency

Nefrologia

Volumn 30, Issue 4, 2010, Pages 474-476

  Aghamohammadi, A ^a   Shafiei, A ^a   Abolhassani, H ^a   Sherkat, R ^b   Mahjoub, F ^a   Rezaei, N ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOIDOSIS; CASE REPORT; COMMON VARIABLE IMMUNODEFICIENCY; HUMAN; KIDNEY DISEASE; LETTER; MALE; MIDDLE AGED;

AMYLOIDOSIS; COMMON VARIABLE IMMUNODEFICIENCY; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED;

EID: 77956005169     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2010.May.10280     Document Type: Letter

References (15)

1. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999;92:34-48.[Pubmed]
2. Aghamohammadi A, Farhoudi A, Moin M, Rezaei N, Kouhi A, Pourpak Z, et al. Clinical and immunological features of 65 Iranian patients with common variable immunodeficiency. Clin Diagn Lab Immunol 2005;12:825-32.[Pubmed]
3. Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008;112:277-86.[Pubmed]
4. Kotilainen P, Vuori K, Kainulainen L, Aho H, Saario R, Asola M. Systemic amyloidosis in a patient with hypogammaglobulinemia. J Int Med 1996;240:103-6.
5. Johnston S, Virgo P, Unsworth D. Type 1 diabetes mellitus masking primary antibody deficiency. J Clin Pathol 2000;53:236-7.[Pubmed]
6. Cehk A, Altiparamak M, Pamuk G, Pumak O, Tabak F. Association of secondary amyloidosis with common variable immunodeficiency and tuberclusis. Yonsei Med J 2005;46:847-50.[Pubmed]
7. Soysal D. A case of ommon variable immunodeficiency disease and thyroid amyloidosis. Turk J Med Sci 2009;39:467-73.
8. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.[Pubmed]
9. Naiki H, Gejyo F. Kinetic analysis of amyloid fibril formation. Methods Enzymol 1999;309:305-18.[Pubmed]
10. Coker A, Purvis A, Baker D, Pepys M, Wood S. Molecular chaperone properties of serum amyloid P component. FEBS Lett 2000;473:199-202.
11. Hazenberg B, Van Gameren I, Bijzet J, Jager P, Van Rijswik M. Diagnostic and therapeutic approach of systemic amyloidosis. Neth J Med 2004;62:121-8.[Pubmed]
12. Kainulainen L, Nikoskelainen J, Ruuskanen O. Diagnostic findings in 95 finnish patients with common variable immunodeficiency. J Clin Immunol 2001;21:145-9.[Pubmed]
13. Pipitone N, Fioravanti A, Marcolongo R, Pitzalis C. Articular involvement in the course of primary hypogammaglobulinemia. Recent Prog Med 2001;92:63-7.[Pubmed]
14. Kyle R, Gertz M, Greipp P, Witzig T, Lust J, Lacy M. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202-7.[Pubmed]
15. Nishi S, Alchi B, Imai N, Gejyo F. New advances in renal amyloidosis. Clin Exp Nephrol 2000;12:93-101.